This paper is in the following e-collection/theme issue:

Lung Cancer (36) Patient-Reported Outcome Measures (PROMs) (294) Innovations and Technology in Cancer Care (431) Chemotherapy and Side Effects Management (60)

Published on in Vol 7, No 3 (2021): Jul-Sep

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/26574, first published .
Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study

Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study

Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study

Authors of this article:

Evalien Veldhuijzen1 Author Orcid Image ;   Iris Walraven2 Author Orcid Image ;   José Belderbos1 Author Orcid Image
Article Authors Cited by (8) Tweetations (2) Metrics

Journals

  1. de Rooij B, van den Hurk C, Smaardijk V, Fernandez-Ortega P, Navarro-Martin A, Barberio L, Guckenberger M, Schmid S, Walraven I, Vallow S, Kotsi C, Preusser M, Mosor E, Klok J, Becker A, Milani A, Ninov L, van de Poll-Franse L. Development of an updated, standardized, patient-centered outcome set for lung cancer. Lung Cancer 2022;173:5 View
  2. de Rooij B, van den Hurk C, Smaardijk V, Fernandez-Ortega P, Navarro-Martin A, Barberio L, Guckenberger M, Schmid S, Walraven I, Vallow S, Kotsi C, Preusser M, Mosor E, Klok J, Becker A, Milani A, Ninov L, van de Poll-Franse L. Development of an Updated, Standardized, Patient-Centered Outcome Set for Lung Cancer. SSRN Electronic Journal 2022 View
  3. Veldhuijzen E, Walraven I, Kwint M, Rossi M, Roose L, Janssen T, van de Poll-Franse L, Belderbos J. The Discordance between Patient- and Clinician Reported Outcomes During (Chemo-)Radiation Therapy for Lung Cancer. SSRN Electronic Journal 2022 View
  4. Billingy N, Tromp V, Aaronson N, Hoek R, Bogaard H, Onwuteaka-Philipsen B, van de Poll-Franse L, Hugtenburg J, Belderbos J, Becker-Commissaris A, van den Hurk C, Walraven I, van Walree N, de Jaeger K, Samii S, Lam-Wong W, Koppe F, Stigt J, Herder G, Welling A, Schuurbiers-Siebers O, Smit J, Staal-van den Brekel A, de Jong W. Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial. JNCI: Journal of the National Cancer Institute 2023;115(12):1515 View
  5. Günther M, Hentschel L, Schuler M, Müller T, Schütte K, Ko Y, Schmidt-Wolf I, Jaehde U. Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers. BMC Cancer 2023;23(1) View
  6. Caminiti C, Maglietta G, Arenare L, Di Liello R, Migliaccio G, Barberio D, De Laurentiis M, Di Rella F, Nuzzo F, Pacilio C, Iodice G, Orditura M, Ciardiello F, Di Bella S, Cavanna L, Porta C, Giovanardi F, Ripamonti C, Bilancia D, Aprile G, Ruelle T, Diodati F, Piccirillo M, Iannelli E, Pinto C, Perrone F. Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study. The Breast 2024;77:103781 View
  7. Billingy N, van den Hurk C, N. M. F. Tromp V, van de Poll-Franse L, Onwuteaka-Philipsen B, Hugtenburg J, Bogaard H, Belderbos J, Aaronson N, Walraven I, Becker-Commissaris A, van Walree N, de Jaeger K, Samii S, Lam-Wong W, Koppe F, Stigt J, Herder G, Welling A, Schuurbiers-Siebers O, Smit J, Staal-van den Brekel A, de Jong W. Patient- vs Physician-Initiated Response to Symptom Monitoring and Health-Related Quality of Life. JAMA Network Open 2024;7(8):e2428975 View
  8. Geurts Y, Peters F, Feldman E, Roodhart J, Richir M, Dekker J, Beets G, Cnossen J, Bottenberg P, Intven M, Verheij M, de Ligt K, Walraven I. Using a modified Delphi procedure to select a PRO-CTCAE-based subset for patient-reported symptomatic toxicity monitoring in rectal cancer patients. Quality of Life Research 2024;33(11):3013 View